So we're expecting some 'top line' data re BTX1308 (Psoriasis) hopefully early Q2.........so April perhaps........what I find very compelling about all of BOT's products is their high possibility for 'success via overlap'.........i.e if one is proven successful then there's a very good probability that the others will prove out in addition............
"Atopic dermatitis (and psoriasis) are both T-cell mediated inflammatory diseases of the skin"..........and our AT data for phase 1 looked great.............
"BTX 1204 was twice as effective as vehicle (with efficacy still increasing) and displayed a substantial improvement in the key signs of AD1".......etc etc.
There is a significant demonstrated antimicrobial effect also........
And we have this to consider also......."worldwide Botanix holds the exclusive rights to utilise PermetrexTM for all drugs that treat skin diseases"...........lower dose levels leads to better safety profiles/extended use scenarios and so on.
So we're expecting some 'top line' data re BTX1308 (Psoriasis)...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.005(1.59%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 32.5¢ | 31.0¢ | $1.169M | 3.655M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 274982 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 48600 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
